Related Experiment Video

Updated: Aug 16, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Challenges and successes in developing new therapies for hepatitis C

Raffaele De Francesco1, Giovanni Migliaccio

  • 1Istituto di Ricerche di Biologia Molecolare P. Angeletti, Via Pontina km 30.600, 00040 Pomezia-Rome, Italy. raffaele_defrancesco@merck.com

Nature
|August 19, 2005
PubMed

Insights

Hepatitis C virus (HCV) remains a global health challenge due to chronic infections and disease. New drug combinations are essential to overcome treatment resistance and effectively manage chronic HCV.

Area of Science:

  • Virology
  • Hepatology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection poses a significant, long-term global health threat.
  • Chronic HCV infection leads to substantial disease morbidity and high prevalence worldwide.
  • Existing and emerging treatments face limitations due to potential drug resistance.

Purpose of the Study:

  • To review the current landscape of Hepatitis C virus (HCV) treatment.
  • To highlight the challenges posed by HCV drug resistance.
  • To emphasize the need for combination therapies in managing chronic HCV.

Main Methods:

  • Review of recent proof-of-concept clinical trial data for novel antiviral molecules.
  • Analysis of preclinical evidence regarding the development of drug resistance in HCV.
  • Synthesis of current knowledge on HCV pathogenesis and treatment strategies.

Main Results:

  • Emerging antiviral agents show promise in early-stage clinical trials.
  • Preclinical studies indicate a growing concern for resistance development against new HCV drugs.
  • The long-term efficacy of monotherapies is likely to be compromised by resistance.

Conclusions:

  • Combination therapy using multiple agents is crucial for effectively treating chronic Hepatitis C virus infection.
  • Addressing drug resistance is a key consideration for future HCV treatment regimens.
  • Sustained efforts are needed to combat the global health burden of HCV.

More Related Videos

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...